Stocks · News reference
Galectin Therapeutics Inc. (NASDAQ:GALT) ("Galectin" or the "Company"), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 16.67 percent decrease over losses of $(0.12) per
Read original at benzingaFiled: 2026-08-14 AccNo: 0001140361-26-032946 Size: 887 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarGoldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.
Read original at benzinga